Integral Health Asset Management LLC Buys New Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Integral Health Asset Management LLC acquired a new position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 275,000 shares of the biotechnology company's stock, valued at approximately $5,170,000. Integral Health Asset Management LLC owned approximately 0.22% of Arrowhead Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. R Squared Ltd purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at $38,000. Van ECK Associates Corp raised its position in Arrowhead Pharmaceuticals by 72.3% in the fourth quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 1,250 shares during the period. KBC Group NV raised its position in Arrowhead Pharmaceuticals by 45.9% in the fourth quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock valued at $98,000 after purchasing an additional 1,644 shares during the period. Envestnet Portfolio Solutions Inc. purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at $190,000. Finally, First Citizens Bank & Trust Co. purchased a new stake in Arrowhead Pharmaceuticals in the fourth quarter valued at $205,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Insider Activity

In other news, CEO Christopher Richard Anzalone sold 51,425 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $15.07, for a total value of $774,974.75. Following the transaction, the chief executive officer now owns 4,062,377 shares in the company, valued at approximately $61,220,021.39. This represents a 1.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In the last 90 days, insiders have sold 275,880 shares of company stock worth $4,034,037. 4.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

ARWR has been the topic of a number of research analyst reports. Royal Bank of Canada restated an "outperform" rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. HC Wainwright restated a "buy" rating and issued a $80.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. B. Riley reaffirmed a "buy" rating and issued a $38.00 price objective (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, February 14th. Chardan Capital reaffirmed a "buy" rating and issued a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Tuesday. Finally, StockNews.com raised Arrowhead Pharmaceuticals from a "sell" rating to a "hold" rating in a research note on Wednesday. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $42.13.

Arrowhead Pharmaceuticals Stock Up 2.4%

ARWR traded up $0.37 on Friday, hitting $15.71. 1,821,408 shares of the company were exchanged, compared to its average volume of 1,483,733. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $30.41. The company has a market cap of $2.17 billion, a price-to-earnings ratio of -3.04 and a beta of 0.89. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The firm has a 50-day moving average price of $13.30 and a two-hundred day moving average price of $17.79.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping the consensus estimate of ($0.06) by $2.81. The company had revenue of $542.71 million for the quarter, compared to analyst estimates of $116.27 million. During the same period in the previous year, the firm earned ($1.02) earnings per share. On average, equities analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.